Remedy

Citius Prescription drugs, Inc. Submits Biologics License Software to the U.S. Food and Drug Administration for Denileukin Diftitox for the Remedy of Clients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

CRANFORD, N.J., Sept. 28, 2022 /PRNewswire/ -- Citius Prescribed drugs, Inc. ("Citius" or the "Enterprise") (Nasdaq: CTXR), a late-phase biopharmaceutical...

Phathom Pharmaceuticals Announces Food and drug administration Acceptance for Submitting of Vonoprazan NDA for the Remedy of Erosive Esophagitis

Phathom Prescription drugsFLORHAM PARK, N.J., May 25, 2022 (Globe NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company centered...